ObamaCare: the value of your life

May 1, 2010

This is how a death panel works. In Britain, a man is denied life-extending medicine by the National Health Service because his case wasn’t exceptional:

A CANCER patient has been denied NHS funding for a new cancer drug which could add years to his life.

It means that health specialists will be unable to prescribe Everolimus, which costs about £40,000 a year and can extend lives by up to two years.

Doctors treating Graeme Johnstone, 54, from Middleton St George, near Darlington applied to the local primary care trust for funding for the drug. But NHS County Durham and Darlington rejected the request.

Fully licensed, and widely available in France and Canada, Everolimus, also known as Affinitor, has a proven track record. But so far it is not being made available through the NHS after the body which vets new drugs – the National Institute for Health and Clinical Excellence (Nice) – decided not to recommend it.

Controversially, Nice uses a formula which calculates whether life-extending drugs represent good value for money.

And just what were they valuing against the cost of the drug Mr. Johnstone wants? Could it be the gentleman’s very life?

Makes you want to run out and apply for British citizenship, doesn’t it?

It’s as sure a thing as the sun rising in the East in the morning: a nationalized health system in which the government determines the price paid for everything inevitably becomes a system in which care is rationed and denied to save money.

Behold the brave new world under ObamaCare.

(via The Jawa Report)


Follow

Get every new post delivered to your Inbox.

Join 13,754 other followers